^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CHEK1 overexpression

i
Other names: CHEK1, CHK1, Checkpoint kinase 1
Entrez ID:
Related biomarkers:
4ms
Identification of CDK1, PBK, and CHEK1 as an Oncogenic Signature in Glioblastoma: A Bioinformatics Approach to Repurpose Dapagliflozin as a Therapeutic Agent. (PubMed, Int J Mol Sci)
The current treatment regimen comprising surgical resectioning, chemotherapy with Temozolomide (TMZ), and adjuvant radiotherapy does not achieve total patient cure. We used in silico molecular docking to analyze and validate our objective to repurpose Dapagliflozin against CDK1/PBK/CHEK1. Our results showed that Dapagliflozin forms putative conventional hydrogen bonds with CDK1, PBK, and CHEK1 and arrests the cell cycle with the lowest energies as Abemaciclib.
Journal
|
CHEK1 (Checkpoint kinase 1) • CDK1 (Cyclin-dependent kinase 1)
|
CDK6 overexpression • CHEK1 overexpression
|
temozolomide • Verzenio (abemaciclib) • Farxiga (dapagliflozin)
6ms
Identification of naturally occurring compounds as alternatives to radiation therapy for treatment of small cell lung cancer. (PubMed, J Biomol Struct Dyn)
MD simulations were performed for the selected protein-ligand complexes and the results were compared to the co-crystallised ligand, 3-(indol-2-yl)indazole. The results showed that compound INC000033832986 could be a natural alternative to the commercial ligand for the prevention of SCLC.Communicated by Ramaswamy H. Sarma.
Journal
|
CHEK1 (Checkpoint kinase 1)
|
CHEK1 overexpression
almost2years
Circ_0011292 knockdown mitigates progression and drug resistance in PTX-resistant non-small-cell lung cancer cells by regulating miR-433-3p/CHEK1 axis. (PubMed, Thorac Cancer)
Circ_0011292 could accelerate PTX resistance and cell malignant progression of NSCLC cells partially through the regulation of circ_0011292/miR-433-3p/CHEK1 axis.
Journal
|
CHEK1 (Checkpoint kinase 1)
|
CHEK1 overexpression
|
paclitaxel
2years
MiR-139-3p Targets CHEK1 Modulating DNA Repair and Cell Viability in Lung Squamous Carcinoma Cells. (PubMed, Mol Biotechnol)
The results indicated that the effects of miR-139-3p on the LUSC cell phenotypes could be blocked by overexpressing CHEK1. In conclusion, our study provides a novel insight into the regulatory role of miR-139-3p in the development of LUSC.
Journal
|
CHEK1 (Checkpoint kinase 1) • MIR139 (MicroRNA 139)
|
CHEK1 overexpression
over2years
CHEK1: a hub gene related to poor prognosis for lung adenocarcinoma. (PubMed, Biomark Med)
Cell clusters with CHEK1 expression were more prone to metastasis and epithelial-to-mesenchymal transition. CHEK1 might potentially act as a prognostic biomarker for LUAD.
Journal
|
CHEK1 (Checkpoint kinase 1)
|
CHEK1 overexpression
almost3years
CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma. (PubMed, Mol Cancer)
Our findings suggest that targeting the enzymatic catalytic center encoded by CHEK1 mRNA and circCHEK1_246aa is a promising therapeutic modality to target both MM cells and BM niche.
Journal
|
CHEK1 (Checkpoint kinase 1) • NFATC1 (Nuclear Factor Of Activated T Cells 1)
|
CHEK1 overexpression
3years
EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells. (PubMed, Theranostics)
Finally, in clinical samples, ovarian cancer patients with high levels of EZH2 and CHK1 not only were more resistant to platinum but also had a poorer prognosis. Our data revealed a previously unidentified functional and mechanistic link between EZH2 levels, CHK1 signaling activation, and ovarian CSCs and provided strong evidence that EZH2 promotes ovarian cancer chemoresistance and recurrence.
Journal
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • CHEK1 (Checkpoint kinase 1)
|
CHEK1 overexpression